Stockwatch: MS - not a zero sum game
This article was originally published in Scrip
Executive Summary
As the first full week of the first quarter 2011 earnings season got underway, lacklustre results from Gilead Sciences, Abbott and Lilly were relegated to the shade by Biogen Idec’s quarterly announcement on 21 April resulting in its stock rising by more than 15%, adding $4 billion to its market cap.